Form 4: Ikena Oncology CFO Receives Stock Grant
Insider Transaction (Form 4)
Yanina Grant-Huerta, Chief Financial Officer of Ikena Oncology, Inc., reported multiple transactions in common stock on August 14, 2026.
Summary
- Grant/award: acquired 65,000 Common Stock on August 14, 2026; holds 65,000 after (Direct).
- Grant/award: acquired 39,000 Common Stock on August 14, 2026; holds 104,000 after (Direct).
- Grant/award: acquired 56,000 Employee Stock Option (right to buy) on August 14, 2026; holds 56,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Yanina Grant-Huerta — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Grant/award | Common Stock | 65,000 | — | — | 65,000 |
| 2026-08-14 | Grant/award | Common Stock | 39,000 | — | — | 104,000 |
| 2026-08-14 | Grant/award | Employee Stock Option (right to buy) | 56,000 | — | — | 56,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Grant/award (65,000 shares) |
| 2026-08-14 | Grant/award (39,000 shares) |
| 2026-08-14 | Grant/award (56,000 shares) |
Keywords
insider transaction, Form 4, IMA, ImageneBio, Inc., neutral, Yanina Grant-Huerta
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.